Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 9, Issue 7, Pages 537-550Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd3141
Keywords
-
Funding
- Welch Foundation [F-1654]
- National Institute of General Medical Sciences [R01GM077040]
Ask authors/readers for more resources
Nucleic acid aptamers can be selected from pools of random-sequence oligonucleotides to bind a wide range of biomedically relevant proteins with affinities and specificities that are comparable to antibodies. Aptamers exhibit significant advantages relative to protein therapeutics in terms of size, synthetic accessibility and modification by medicinal chemistry. Despite these properties, aptamers have been slow to reach the marketplace, with only one aptamer-based drug receiving approval so far. A series of aptamers currently in development may change how nucleic acid therapeutics are perceived. It is likely that in the future, aptamers will increasingly find use in concert with other therapeutic molecules and modalities.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available